Clinical Trial Update: Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating centanafadine as monotherapy or as an SSRI adjunct in adults with major depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Centanafadine (centanafadine)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED